2025 National Talks Day 3 Morning Session: AstraZeneca representatives have completed all negotiations and left the venue.

According to information obtained by reporters from the on-site negotiations of the 2025 national medical insurance catalog and the commercial insurance innovative drug catalog pricing negotiations, on the morning of the third day of negotiations, representatives of companies such as Lilly and AstraZeneca completed negotiations and left one after another. Lilly's China president and general manager, Deheran, led the team out without saying a word and quickly left. AstraZeneca's vice president, Huang Bin, revealed to reporters that the company has completed all negotiations on this year's national negotiations agenda and will not be present for the next few days. It is reported that AstraZeneca's AKT inhibitor capivasertib tablets, malate acalutinib tablets, and bevacizumab injection have passed the preliminary review of the national negotiations and are expected to qualify for medical insurance for the first time, with the classic EGFR-TKI osimertinib mesylate tablets targeting indication expansion this time.